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the responsiveness to treatment, accuracy (sensitivity, specificity and positive predictive rates) of screening for all different metabolic disorders, and mortality.
Modelling
A decision model was constructed to simulate the clinical management of newborns screened for different metabolic disorders. First, each screening strategy was individually compared with no screening. Then, the model evaluated the cost-effectiveness of expanding the screening strategy to other diseases (up to 21). All diseases were grouped into three levels of severity: neonatal, classical, severe, or early onset forms of the disease; later onset, chronic, or milder forms of the disease; and mild variations that would not be detected or treated without newborn screening.
Key assumptions made in the model were reported. All initially positive screening results were confirmed with a second tandem MS/MS analysis before the patient was contacted. Positive results from MS/MS testing were confirmed with other technologies before a final diagnosis was made. The authors reported the structure of the decision tree and described the main pathways. The time horizon of the analysis was not explicitly stated but it might have been lifetime.
Sources searched to identify primary studies
The positive predictive rates came from a pilot study in California. The mortality rates were derived from the 2000 World Health Organization Life Table for Canada. There was little information on the other sources of data. Expert opinion was often combined with published sources to estimate epidemiological and clinical parameters.
Methods used to judge relevance and validity, and for extracting data
The method used to obtain the clinical data was not reported, thus the primary studies might have been identified selectively. Data were obtained from Canadian sources, when available.
Measure of benefits used in the economic analysis
The summary benefit measure used was the expected number of life-years (LYs) associated with each screening strategy under examination. The LYs were estimated using the decision model and were discounted at an annual rate of 3%.
Direct costs
The analysis of the costs was restricted to the perspective of the third-party payer. It included the costs of start-up (equipment, training, analysis software and maintenance), confirmatory tests (tests and counselling), treatment, hospitalisation, and costs associated with social services and education. The unit costs and the quantities of resources used were not presented separately. However, annual costs were reported for each category included in the analysis. The start-up costs were based on an assumed MS/MS throughput per year. The costs of confirmatory tests came from the Ministry of Health Schedule of Laboratory Fees. Treatment costs came from multiple sources and hospital costs were derived from Ontario sources. Additional costs associated with social services and education were derived from published studies. Discounting was relevant, as long-term costs were evaluated, and an annual rate of 3% was used. The costs were inflated to 2004 values using the Canadian Health Care Price Index.
Indirect Costs
Productivity costs were not considered.
Currency
Canadian dollars (CAD).
Sensitivity analysis
A univariate sensitivity analysis was performed. This assessed the robustness of the cost-effectiveness ratios to variations in all clinical and economic inputs of the decision model. The sources of the alternative values examined in the sensitivity analysis were not stated. Four pessimistic scenarios were also evaluated in which both the sensitivity and specificity of MS/MS were reduced in combination with increased costs and reduced life expectancy.
Estimated benefits used in the economic analysis
The expected LYs gained with each screening strategy evaluated independently per infant ranged from 0.000000134 with glutaric acidemia Type II to 0.0000965 with medium-chain acyl-CoA dehydrogenase deficiency.
In a cohort of 130,000 babies (estimated annual birth cohort in Ontario), screening for all 21 diseases would result in 32 early diagnoses each year and 107 LYs gained across the whole cohort.
Cost results
The estimated total costs per infant associated with each screening strategy evaluated independently ranged from CAD 17.41 for PKU and its variants to CAD 62.89 for arginosuccinic aciduria.
The costs were mainly related to start-up and base operation costs. Thus, excluding start-up costs, the incremental cost of expanding the screening strategy to another metabolic disorder was very low (less than US$2), except for urea cycle disorders.
Synthesis of costs and benefits
Incremental cost-effectiveness ratios were calculated to combine the costs and benefits of the alternative screening strategies.
With respect to no screening, the incremental cost per LY gained ranged from CAD 221,719 with screening for HMG-CoA lyase deficiency to CAD 142,462,687 with screening for medium-chain acyl-CoA dehydrogenase deficiency.
The four most cost-effective diseases to screen for were HMG-CoA lyase deficiency (CAD 221,719), MCADD (CAD 253,161), methylmalonic acidemia (CAD 253,927) and 3-methylcrotonyl-CoA carboxylase deficiency (CAD 266,991), assuming each was screened for independently.
Thus, none of the screening strategies could be considered cost-effective when evaluated individually.
In particular, the incremental cost per LY gained for PKU screening (current strategy) compared with no screening was CAD 5,492,114.
However, the cost-effectiveness of adding additional diseases to a screening programme was much lower. In a scenario in which PKU screening has absorbed all the fixed costs, expanding the screening to a third disease (maple syrup urine disease) cost CAD 15,426 per LY gained.
Adding the seventh disease (glutaric acidemia Type I) to the bundle cost CAD 48,071 per LY gained, while adding the 14th disease (carnitine/acylcarnitine translocase deficiency) cost CAD 95,000 per LY gained. Adding the 15th disease (tyrosinemia Type I) produced instead an incremental cost of CAD 309,409 per LY gained.
